FDA approves Dupixent for chronic obstructive pulmonary disease
The U.S. Food and Drug Administration has approved Regeneron's Dupixent (dupilumab) as an add-on maintenance treatment for ...
With $115M more, Triveni accelerates immune drug work
The biotech, which has now raised more than $200 million since launch, is advancing an eczema treatment that could start ...
FierceBiotech3h
Triveni ropes in $115M series B less than a year after $92M fundraise
Triveni Bio has roped in $115 million in series B funds to advance preclinical antibody programs designed to treat ...
Dupixent® (dupilumab) Approved in the U.S. as the First-ever Biologic Medicine for Patients with COPD
Dupixent is indicated for the approximately 300,000 adults in the U.S. with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype Following recent ...